|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000204252 |
Summary for HLA-DOA |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000204252 | Gene symbol | HLA-DOA |
| Gene name | major histocompatibility complex, class II, DO alpha | |
| HGNC | 4936 | |
| Entrez ID | 3111 | |
| Gene type | protein_coding | |
| Synonyms | HLA-DOA|HLA-D0-alpha | |
| UniProtAcc | P06340 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for HLA-DOA |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| HLA-DOA | 3.23e+03 | -1.28e+00 | 2.47e-01 | -5.17e+00 | 2.31e-07 | 9.03e-07 | LUAD |
| HLA-DOA | 2.22e+03 | 1.34e+00 | 4.25e-01 | 3.17e+00 | 1.54e-03 | 4.04e-03 | THCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for HLA-DOA |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for HLA-DOA |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LIHC | cg10397527 | chr6:33009440 | CGI:chr6:33007907-33008149 | promoter,gene body | 3.20e-01 | 2.15e-01 | 3.34e+00 | 8.33e-04 | 3.29e-03 | 1.04e-01 |
| MESO | cg23220637 | chr6:33009028 | CGI:chr6:33007907-33008149 | promoter,gene body | 7.87e-01 | 6.50e-01 | 3.53e+00 | 4.10e-04 | 2.27e-03 | 1.37e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg16673446 | chr6:33008148 | CGI:chr6:33007907-33008149 | promoter,gene body,CDS,UTR,exon | 7.64e-01 | 8.74e-01 | -2.41e+00 | 1.58e-02 | 1.94e-02 | -1.10e-01 |
| LUAD | cg24696151 | chr6:33008209 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 7.01e-01 | 8.49e-01 | -4.18e+00 | 2.95e-05 | 1.02e-04 | -1.48e-01 |
| LUAD | cg18307545 | chr6:33008214 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 7.99e-01 | 9.22e-01 | -4.23e+00 | 2.37e-05 | 8.51e-05 | -1.22e-01 |
| LUAD | cg25061610 | chr6:33008272 | CGI:chr6:33007907-33008149 | promoter,exon,gene body | 5.23e-01 | 6.64e-01 | -5.06e+00 | 4.17e-07 | 3.48e-06 | -1.41e-01 |
| LUAD | cg16914277 | chr6:33010276 | CGI:chr6:33007907-33008149 | promoter | 7.47e-01 | 8.85e-01 | -3.30e+00 | 9.73e-04 | 1.90e-03 | -1.38e-01 |
| LUAD | cg11076970 | chr6:33010419 | CGI:chr6:33007907-33008149 | promoter | 8.38e-01 | 9.44e-01 | -3.40e+00 | 6.84e-04 | 1.41e-03 | -1.06e-01 |
| LUAD | cg01720176 | chr6:33010504 | CGI:chr6:33007907-33008149 | promoter | 7.15e-01 | 8.62e-01 | -2.53e+00 | 1.13e-02 | 1.48e-02 | -1.47e-01 |
| LUAD | cg00988577 | chr6:33010771 | CGI:chr6:33007907-33008149 | promoter | 8.11e-01 | 9.15e-01 | -2.44e+00 | 1.46e-02 | 1.82e-02 | -1.04e-01 |
| THCA | cg05408403 | chr6:33010494 | CGI:chr6:33007907-33008149 | promoter | 6.64e-01 | 5.56e-01 | 2.02e+00 | 4.29e-02 | 4.51e-02 | 1.08e-01 |
| HNSC | cg16673446 | chr6:33008148 | CGI:chr6:33007907-33008149 | promoter,gene body,CDS,UTR,exon | 7.52e-01 | 8.59e-01 | -2.52e+00 | 1.16e-02 | 1.45e-02 | -1.06e-01 |
| HNSC | cg07294785 | chr6:33008241 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 8.35e-01 | 9.49e-01 | -2.02e+00 | 4.34e-02 | 4.43e-02 | -1.15e-01 |
| HNSC | cg24696151 | chr6:33008209 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 6.82e-01 | 8.34e-01 | -4.07e+00 | 4.73e-05 | 1.38e-04 | -1.53e-01 |
| HNSC | cg18307545 | chr6:33008214 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 8.05e-01 | 9.16e-01 | -3.01e+00 | 2.61e-03 | 4.10e-03 | -1.11e-01 |
| HNSC | cg25061610 | chr6:33008272 | CGI:chr6:33007907-33008149 | promoter,exon,gene body | 4.91e-01 | 6.33e-01 | -4.66e+00 | 3.22e-06 | 1.50e-05 | -1.42e-01 |
| HNSC | cg04615290 | chr6:33010352 | CGI:chr6:33007907-33008149 | promoter | 6.42e-01 | 7.77e-01 | -2.35e+00 | 1.86e-02 | 2.17e-02 | -1.35e-01 |
| HNSC | cg13132775 | chr6:33010363 | CGI:chr6:33007907-33008149 | promoter | 5.57e-01 | 7.27e-01 | -3.38e+00 | 7.16e-04 | 1.37e-03 | -1.70e-01 |
| HNSC | cg05408403 | chr6:33010494 | CGI:chr6:33007907-33008149 | promoter | 4.64e-01 | 6.86e-01 | -3.15e+00 | 1.66e-03 | 2.79e-03 | -2.21e-01 |
| HNSC | cg01720176 | chr6:33010504 | CGI:chr6:33007907-33008149 | promoter | 5.79e-01 | 7.77e-01 | -3.33e+00 | 8.73e-04 | 1.61e-03 | -1.98e-01 |
| HNSC | cg06504039 | chr6:33010602 | CGI:chr6:33007907-33008149 | promoter | 5.59e-01 | 6.65e-01 | -2.27e+00 | 2.35e-02 | 2.64e-02 | -1.06e-01 |
| HNSC | cg05043389 | chr6:33010739 | CGI:chr6:33007907-33008149 | promoter | 7.72e-01 | 8.83e-01 | -2.23e+00 | 2.58e-02 | 2.86e-02 | -1.11e-01 |
| HNSC | cg00988577 | chr6:33010771 | CGI:chr6:33007907-33008149 | promoter | 7.57e-01 | 8.92e-01 | -3.25e+00 | 1.13e-03 | 2.02e-03 | -1.35e-01 |
| LUSC | cg00067032 | chr6:33008039 | CGI:chr6:33007907-33008149 | promoter,gene body,CDS,UTR,exon | 8.42e-01 | 9.69e-01 | -3.43e+00 | 6.06e-04 | 1.87e-03 | -1.26e-01 |
| LUSC | cg10620866 | chr6:33008098 | CGI:chr6:33007907-33008149 | promoter,gene body,CDS,UTR,exon | 8.54e-01 | 9.75e-01 | -3.38e+00 | 7.32e-04 | 2.12e-03 | -1.21e-01 |
| LUSC | cg18477188 | chr6:33008108 | CGI:chr6:33007907-33008149 | promoter,gene body,CDS,UTR,exon | 8.68e-01 | 9.77e-01 | -2.78e+00 | 5.45e-03 | 8.70e-03 | -1.09e-01 |
| LUSC | cg16673446 | chr6:33008148 | CGI:chr6:33007907-33008149 | promoter,gene body,CDS,UTR,exon | 7.05e-01 | 8.60e-01 | -2.53e+00 | 1.13e-02 | 1.52e-02 | -1.55e-01 |
| LUSC | cg07173283 | chr6:33007813 | CGI:chr6:33007907-33008149 | promoter,exon,gene body | 6.36e-01 | 8.88e-01 | -4.20e+00 | 2.65e-05 | 5.26e-04 | -2.52e-01 |
| LUSC | cg14630099 | chr6:33007925 | CGI:chr6:33007907-33008149 | promoter,gene body | 8.35e-01 | 9.39e-01 | -3.42e+00 | 6.27e-04 | 1.91e-03 | -1.04e-01 |
| LUSC | cg24696151 | chr6:33008209 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 6.42e-01 | 8.62e-01 | -4.07e+00 | 4.71e-05 | 5.50e-04 | -2.20e-01 |
| LUSC | cg18307545 | chr6:33008214 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 7.71e-01 | 9.31e-01 | -3.68e+00 | 2.34e-04 | 1.06e-03 | -1.61e-01 |
| LUSC | cg14144933 | chr6:33008217 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 7.00e-01 | 8.15e-01 | -2.97e+00 | 3.00e-03 | 5.60e-03 | -1.16e-01 |
| LUSC | cg25061610 | chr6:33008272 | CGI:chr6:33007907-33008149 | promoter,exon,gene body | 4.96e-01 | 6.73e-01 | -4.17e+00 | 3.07e-05 | 5.26e-04 | -1.78e-01 |
| LUSC | cg17777731 | chr6:33008354 | CGI:chr6:33007907-33008149 | promoter,exon,gene body | 6.10e-01 | 8.97e-01 | -4.14e+00 | 3.47e-05 | 5.29e-04 | -2.87e-01 |
| LUSC | cg13336690 | chr6:33008707 | CGI:chr6:33007907-33008149 | promoter,gene body | 5.68e-01 | 8.18e-01 | -4.11e+00 | 4.00e-05 | 5.36e-04 | -2.49e-01 |
| LUSC | cg23220637 | chr6:33009028 | CGI:chr6:33007907-33008149 | promoter,gene body | 4.32e-01 | 5.86e-01 | -3.19e+00 | 1.41e-03 | 3.27e-03 | -1.53e-01 |
| LUSC | cg03780648 | chr6:33009049 | CGI:chr6:33007907-33008149 | promoter,gene body | 4.05e-01 | 5.64e-01 | -3.50e+00 | 4.66e-04 | 1.59e-03 | -1.60e-01 |
| LUSC | cg27213800 | chr6:33009081 | CGI:chr6:33007907-33008149 | promoter,gene body | 3.97e-01 | 5.30e-01 | -3.47e+00 | 5.18e-04 | 1.69e-03 | -1.33e-01 |
| LUSC | cg15630950 | chr6:33009120 | CGI:chr6:33007907-33008149 | promoter,gene body | 4.11e-01 | 5.16e-01 | -2.15e+00 | 3.14e-02 | 3.42e-02 | -1.05e-01 |
| LUSC | cg16914277 | chr6:33010276 | CGI:chr6:33007907-33008149 | promoter | 6.91e-01 | 9.08e-01 | -3.78e+00 | 1.58e-04 | 8.61e-04 | -2.17e-01 |
| LUSC | cg04615290 | chr6:33010352 | CGI:chr6:33007907-33008149 | promoter | 6.43e-01 | 8.46e-01 | -2.79e+00 | 5.22e-03 | 8.43e-03 | -2.03e-01 |
| LUSC | cg13132775 | chr6:33010363 | CGI:chr6:33007907-33008149 | promoter | 5.72e-01 | 8.17e-01 | -3.36e+00 | 7.84e-04 | 2.21e-03 | -2.45e-01 |
| LUSC | cg11076970 | chr6:33010419 | CGI:chr6:33007907-33008149 | promoter | 7.89e-01 | 9.58e-01 | -3.83e+00 | 1.26e-04 | 7.73e-04 | -1.70e-01 |
| LUSC | cg01715800 | chr6:33010456 | CGI:chr6:33007907-33008149 | promoter | 8.22e-01 | 9.47e-01 | -3.25e+00 | 1.13e-03 | 2.83e-03 | -1.25e-01 |
| LUSC | cg01720176 | chr6:33010504 | CGI:chr6:33007907-33008149 | promoter | 6.39e-01 | 8.64e-01 | -2.51e+00 | 1.21e-02 | 1.60e-02 | -2.26e-01 |
| LUSC | cg06504039 | chr6:33010602 | CGI:chr6:33007907-33008149 | promoter | 5.71e-01 | 9.32e-01 | -4.30e+00 | 1.74e-05 | 5.26e-04 | -3.61e-01 |
| LUSC | cg05043389 | chr6:33010739 | CGI:chr6:33007907-33008149 | promoter | 7.58e-01 | 9.39e-01 | -3.91e+00 | 9.07e-05 | 6.71e-04 | -1.81e-01 |
| LUSC | cg24476363 | chr6:33010941 | CGI:chr6:33007907-33008149 | promoter | 7.15e-01 | 9.48e-01 | -4.13e+00 | 3.61e-05 | 5.31e-04 | -2.33e-01 |
| COAD | cg10397527 | chr6:33009440 | CGI:chr6:33007907-33008149 | promoter,gene body | 4.33e-01 | 2.79e-01 | 2.12e+00 | 3.37e-02 | 3.70e-02 | 1.54e-01 |
| COAD | cg05683739 | chr6:33010998 | CGI:chr6:33007907-33008149 | promoter | 8.15e-01 | 9.51e-01 | -2.75e+00 | 6.04e-03 | 9.61e-03 | -1.36e-01 |
| COAD | cg24696151 | chr6:33008209 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 5.88e-01 | 6.95e-01 | -2.37e+00 | 1.80e-02 | 2.28e-02 | -1.07e-01 |
| COAD | cg18307545 | chr6:33008214 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 7.34e-01 | 8.84e-01 | -2.49e+00 | 1.27e-02 | 1.73e-02 | -1.50e-01 |
| COAD | cg17777731 | chr6:33008354 | CGI:chr6:33007907-33008149 | promoter,exon,gene body | 3.90e-01 | 5.69e-01 | -3.79e+00 | 1.50e-04 | 4.85e-04 | -1.79e-01 |
| COAD | cg06504039 | chr6:33010602 | CGI:chr6:33007907-33008149 | promoter | 4.61e-01 | 6.16e-01 | -2.87e+00 | 4.07e-03 | 7.00e-03 | -1.55e-01 |
| COAD | cg00988577 | chr6:33010771 | CGI:chr6:33007907-33008149 | promoter | 5.76e-01 | 7.61e-01 | -2.12e+00 | 3.37e-02 | 3.70e-02 | -1.85e-01 |
| BLCA | cg14630099 | chr6:33007925 | CGI:chr6:33007907-33008149 | promoter,gene body | 8.02e-01 | 9.28e-01 | -2.87e+00 | 4.10e-03 | 6.95e-03 | -1.26e-01 |
| BLCA | cg02115397 | chr6:33008073 | CGI:chr6:33007907-33008149 | promoter,gene body,CDS,UTR,exon | 8.30e-01 | 9.53e-01 | -2.55e+00 | 1.08e-02 | 1.50e-02 | -1.23e-01 |
| BLCA | cg12890605 | chr6:33008082 | CGI:chr6:33007907-33008149 | promoter,gene body,CDS,UTR,exon | 7.62e-01 | 8.91e-01 | -3.14e+00 | 1.70e-03 | 3.45e-03 | -1.30e-01 |
| BLCA | cg18307545 | chr6:33008214 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 7.31e-01 | 8.77e-01 | -1.97e+00 | 4.85e-02 | 4.88e-02 | -1.46e-01 |
| BLCA | cg13336690 | chr6:33008707 | CGI:chr6:33007907-33008149 | promoter,gene body | 5.69e-01 | 7.57e-01 | -3.32e+00 | 8.97e-04 | 2.08e-03 | -1.89e-01 |
| BLCA | cg08147094 | chr6:33009897 | CGI:chr6:33007907-33008149 | promoter | 8.57e-01 | 7.53e-01 | 2.39e+00 | 1.70e-02 | 2.15e-02 | 1.04e-01 |
| BLCA | cg01715800 | chr6:33010456 | CGI:chr6:33007907-33008149 | promoter | 7.32e-01 | 9.28e-01 | -3.34e+00 | 8.27e-04 | 1.96e-03 | -1.96e-01 |
| BLCA | cg05408403 | chr6:33010494 | CGI:chr6:33007907-33008149 | promoter | 4.24e-01 | 7.31e-01 | -2.73e+00 | 6.36e-03 | 9.86e-03 | -3.07e-01 |
| BLCA | cg05043389 | chr6:33010739 | CGI:chr6:33007907-33008149 | promoter | 6.65e-01 | 8.92e-01 | -3.14e+00 | 1.68e-03 | 3.41e-03 | -2.27e-01 |
| LIHC | cg16673446 | chr6:33008148 | CGI:chr6:33007907-33008149 | promoter,gene body,CDS,UTR,exon | 5.54e-01 | 8.55e-01 | -4.38e+00 | 1.17e-05 | 3.13e-05 | -3.02e-01 |
| LIHC | cg20024110 | chr6:33009931 | CGI:chr6:33007907-33008149 | promoter | 4.45e-01 | 5.55e-01 | -2.02e+00 | 4.33e-02 | 4.41e-02 | -1.10e-01 |
| LIHC | cg17313945 | chr6:33010206 | CGI:chr6:33007907-33008149 | promoter | 3.91e-01 | 5.77e-01 | -4.60e+00 | 4.14e-06 | 1.27e-05 | -1.86e-01 |
| LIHC | cg04615290 | chr6:33010352 | CGI:chr6:33007907-33008149 | promoter | 4.30e-01 | 6.61e-01 | -4.38e+00 | 1.18e-05 | 3.17e-05 | -2.31e-01 |
| LIHC | cg13132775 | chr6:33010363 | CGI:chr6:33007907-33008149 | promoter | 3.87e-01 | 5.93e-01 | -4.23e+00 | 2.30e-05 | 5.67e-05 | -2.05e-01 |
| LIHC | cg01715800 | chr6:33010456 | CGI:chr6:33007907-33008149 | promoter | 6.09e-01 | 8.33e-01 | -2.91e+00 | 3.58e-03 | 4.91e-03 | -2.24e-01 |
| LIHC | cg05408403 | chr6:33010494 | CGI:chr6:33007907-33008149 | promoter | 3.54e-01 | 5.88e-01 | -2.80e+00 | 5.05e-03 | 6.66e-03 | -2.34e-01 |
| LIHC | cg01720176 | chr6:33010504 | CGI:chr6:33007907-33008149 | promoter | 4.70e-01 | 7.10e-01 | -2.61e+00 | 9.13e-03 | 1.12e-02 | -2.40e-01 |
| LIHC | cg06504039 | chr6:33010602 | CGI:chr6:33007907-33008149 | promoter | 5.97e-01 | 8.42e-01 | -3.56e+00 | 3.76e-04 | 6.65e-04 | -2.45e-01 |
| LIHC | cg00988577 | chr6:33010771 | CGI:chr6:33007907-33008149 | promoter | 5.57e-01 | 8.53e-01 | -4.86e+00 | 1.17e-06 | 4.25e-06 | -2.96e-01 |
| LIHC | cg18278290 | chr6:33010793 | CGI:chr6:33007907-33008149 | promoter | 8.13e-01 | 9.27e-01 | -3.44e+00 | 5.89e-04 | 9.90e-04 | -1.14e-01 |
| LIHC | cg03546401 | chr6:33010833 | CGI:chr6:33007907-33008149 | promoter | 8.32e-01 | 9.41e-01 | -3.29e+00 | 1.00e-03 | 1.59e-03 | -1.08e-01 |
| LIHC | cg24476363 | chr6:33010941 | CGI:chr6:33007907-33008149 | promoter | 4.84e-01 | 7.57e-01 | -5.08e+00 | 3.74e-07 | 1.60e-06 | -2.73e-01 |
| KIRP | cg13132775 | chr6:33010363 | CGI:chr6:33007907-33008149 | promoter | 8.58e-01 | 7.41e-01 | 4.51e+00 | 6.56e-06 | 2.62e-05 | 1.17e-01 |
| CHOL | cg20024110 | chr6:33009931 | CGI:chr6:33007907-33008149 | promoter | 7.90e-01 | 5.59e-01 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 2.31e-01 |
| CHOL | cg17313945 | chr6:33010206 | CGI:chr6:33007907-33008149 | promoter | 7.26e-01 | 5.54e-01 | 2.14e+00 | 3.25e-02 | 3.87e-02 | 1.72e-01 |
| CHOL | cg04615290 | chr6:33010352 | CGI:chr6:33007907-33008149 | promoter | 8.53e-01 | 6.71e-01 | 3.02e+00 | 2.51e-03 | 1.19e-02 | 1.82e-01 |
| CHOL | cg13132775 | chr6:33010363 | CGI:chr6:33007907-33008149 | promoter | 8.10e-01 | 6.66e-01 | 2.21e+00 | 2.70e-02 | 3.50e-02 | 1.44e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg17214455 | chr6:33009361 | CGI:chr6:33007907-33008149 | promoter,gene body | 4.51e-01 | 2.84e-01 | 9.66e+00 | 4.55e-22 | 2.95e-21 | 1.66e-01 |
| BRCA | cg07294785 | chr6:33008241 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 8.22e-01 | 9.46e-01 | -5.64e+00 | 1.68e-08 | 3.67e-08 | -1.24e-01 |
| BRCA | cg10397527 | chr6:33009440 | CGI:chr6:33007907-33008149 | promoter,gene body | 4.99e-01 | 2.34e-01 | 9.97e+00 | 2.02e-23 | 1.48e-22 | 2.64e-01 |
| BRCA | cg07173283 | chr6:33007813 | CGI:chr6:33007907-33008149 | promoter,exon,gene body | 6.37e-01 | 8.52e-01 | -1.16e+01 | 4.29e-31 | 7.16e-30 | -2.15e-01 |
| BRCA | cg24696151 | chr6:33008209 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 7.29e-01 | 8.53e-01 | -7.62e+00 | 2.60e-14 | 8.98e-14 | -1.25e-01 |
| BRCA | cg18307545 | chr6:33008214 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 8.26e-01 | 9.35e-01 | -8.81e+00 | 1.31e-18 | 6.30e-18 | -1.09e-01 |
| BRCA | cg25061610 | chr6:33008272 | CGI:chr6:33007907-33008149 | promoter,exon,gene body | 5.62e-01 | 6.98e-01 | -1.01e+01 | 5.70e-24 | 4.39e-23 | -1.37e-01 |
| BRCA | cg17777731 | chr6:33008354 | CGI:chr6:33007907-33008149 | promoter,exon,gene body | 6.96e-01 | 8.87e-01 | -1.11e+01 | 9.38e-29 | 1.18e-27 | -1.92e-01 |
| BRCA | cg13336690 | chr6:33008707 | CGI:chr6:33007907-33008149 | promoter,gene body | 6.06e-01 | 8.12e-01 | -1.13e+01 | 1.46e-29 | 2.02e-28 | -2.06e-01 |
| BRCA | cg23220637 | chr6:33009028 | CGI:chr6:33007907-33008149 | promoter,gene body | 6.08e-01 | 7.79e-01 | -1.00e+01 | 1.25e-23 | 9.33e-23 | -1.72e-01 |
| BRCA | cg03780648 | chr6:33009049 | CGI:chr6:33007907-33008149 | promoter,gene body | 5.75e-01 | 7.06e-01 | -8.53e+00 | 1.44e-17 | 6.40e-17 | -1.32e-01 |
| BRCA | cg27213800 | chr6:33009081 | CGI:chr6:33007907-33008149 | promoter,gene body | 4.60e-01 | 5.68e-01 | -8.80e+00 | 1.40e-18 | 6.74e-18 | -1.08e-01 |
| BRCA | cg26168907 | chr6:33009446 | CGI:chr6:33007907-33008149 | promoter,gene body | 5.13e-01 | 3.03e-01 | 1.04e+01 | 2.03e-25 | 1.80e-24 | 2.10e-01 |
| BRCA | cg04809274 | chr6:33009477 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 4.17e-01 | 2.32e-01 | 1.01e+01 | 7.86e-24 | 5.98e-23 | 1.85e-01 |
| BRCA | cg24396358 | chr6:33009623 | CGI:chr6:33007907-33008149 | promoter | 2.17e-01 | 1.08e-01 | 6.06e+00 | 1.35e-09 | 3.24e-09 | 1.10e-01 |
| BRCA | cg16914277 | chr6:33010276 | CGI:chr6:33007907-33008149 | promoter | 7.25e-01 | 9.03e-01 | -1.01e+01 | 4.51e-24 | 3.51e-23 | -1.78e-01 |
| BRCA | cg11076970 | chr6:33010419 | CGI:chr6:33007907-33008149 | promoter | 8.47e-01 | 9.51e-01 | -8.80e+00 | 1.35e-18 | 6.50e-18 | -1.04e-01 |
| BRCA | cg05408403 | chr6:33010494 | CGI:chr6:33007907-33008149 | promoter | 5.38e-01 | 7.77e-01 | -4.19e+00 | 2.81e-05 | 4.48e-05 | -2.39e-01 |
| BRCA | cg01720176 | chr6:33010504 | CGI:chr6:33007907-33008149 | promoter | 6.60e-01 | 8.06e-01 | -3.81e+00 | 1.42e-04 | 2.08e-04 | -1.45e-01 |
| BRCA | cg06504039 | chr6:33010602 | CGI:chr6:33007907-33008149 | promoter | 5.78e-01 | 8.21e-01 | -1.04e+01 | 1.72e-25 | 1.53e-24 | -2.43e-01 |
| BRCA | cg05043389 | chr6:33010739 | CGI:chr6:33007907-33008149 | promoter | 7.69e-01 | 8.94e-01 | -5.44e+00 | 5.47e-08 | 1.14e-07 | -1.25e-01 |
| BRCA | cg24476363 | chr6:33010941 | CGI:chr6:33007907-33008149 | promoter | 7.50e-01 | 9.31e-01 | -1.05e+01 | 1.03e-25 | 9.41e-25 | -1.82e-01 |
| KIRC | cg07294785 | chr6:33008241 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 8.90e-01 | 7.18e-01 | 3.27e+00 | 1.07e-03 | 4.67e-03 | 1.72e-01 |
| KIRC | cg06504039 | chr6:33010602 | CGI:chr6:33007907-33008149 | promoter | 9.26e-01 | 8.08e-01 | 3.58e+00 | 3.48e-04 | 3.08e-03 | 1.18e-01 |
| LUAD | cg15630950 | chr6:33009120 | CGI:chr6:33007907-33008149 | promoter,gene body | 4.52e-01 | 5.54e-01 | -2.33e+00 | 2.00e-02 | 2.59e-02 | -1.01e-01 |
| LIHC | cg15630950 | chr6:33009120 | CGI:chr6:33007907-33008149 | promoter,gene body | 4.50e-01 | 6.02e-01 | -2.88e+00 | 3.98e-03 | 6.71e-03 | -1.52e-01 |
| KIRP | cg07294785 | chr6:33008241 | CGI:chr6:33007907-33008149 | promoter,exon,CDS,gene body | 9.03e-01 | 7.46e-01 | 3.94e+00 | 8.09e-05 | 1.09e-03 | 1.56e-01 |
| KIRP | cg17777731 | chr6:33008354 | CGI:chr6:33007907-33008149 | promoter,exon,gene body | 8.56e-01 | 7.44e-01 | 3.20e+00 | 1.39e-03 | 4.73e-03 | 1.13e-01 |
Top |
Exon skipping events with PSI in TCGA for HLA-DOA |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for HLA-DOA |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| KIRC | HLA-DOA-001 | chr6_33005380_- | 8.64e-01 | 8.34e-01 | 3.78e+00 | 1.58e-04 | 3.43e-02 | 2.96e-02 |
| KIRC | HLA-DOA-001 | chr6_33005853_- | 1.65e-01 | 1.79e-01 | -1.99e+00 | 4.63e-02 | 4.96e-02 | -1.39e-02 |
| LUAD | HLA-DOA-001 | chr6_33005380_- | 8.42e-01 | 8.14e-01 | 3.24e+00 | 1.18e-03 | 1.92e-02 | 2.84e-02 |
| LUAD | HLA-DOA-001 | chr6_33005392_- | 1.62e-01 | 1.51e-01 | 2.09e+00 | 3.66e-02 | 4.51e-02 | 1.06e-02 |
| LUAD | HLA-DOA-001 | chr6_33005645_- | 2.55e-01 | 2.33e-01 | 1.98e+00 | 4.79e-02 | 4.90e-02 | 2.28e-02 |
| LUAD | HLA-DOA-001 | chr6_33005675_- | 1.97e-01 | 1.71e-01 | 4.35e+00 | 1.39e-05 | 5.96e-03 | 2.67e-02 |
| LUAD | HLA-DOA-001 | chr6_33005805_- | 1.51e-01 | 1.37e-01 | 2.18e+00 | 2.95e-02 | 4.27e-02 | 1.36e-02 |
| LGG | HLA-DOA-001 | chr6_33005309_- | 2.25e-01 | 1.55e-01 | 2.69e+00 | 7.22e-03 | 4.34e-02 | 7.06e-02 |
| LGG | HLA-DOA-001 | chr6_33005429_- | 2.32e-01 | 1.85e-01 | 2.16e+00 | 3.05e-02 | 4.73e-02 | 4.73e-02 |
| LGG | HLA-DOA-001 | chr6_33005769_- | 1.25e-01 | 1.51e-01 | -2.13e+00 | 3.28e-02 | 4.78e-02 | -2.59e-02 |
| THCA | HLA-DOA-001 | chr6_33005392_- | 1.72e-01 | 1.55e-01 | 2.16e+00 | 3.09e-02 | 4.91e-02 | 1.74e-02 |
| THCA | HLA-DOA-001 | chr6_33005645_- | 2.10e-01 | 2.37e-01 | -2.20e+00 | 2.79e-02 | 4.91e-02 | -2.60e-02 |
| HNSC | HLA-DOA-001 | chr6_33005797_- | 2.73e-01 | 2.40e-01 | 2.11e+00 | 3.52e-02 | 4.54e-02 | 3.26e-02 |
| HNSC | HLA-DOA-001 | chr6_33005808_- | 1.59e-01 | 1.15e-01 | 2.13e+00 | 3.32e-02 | 4.44e-02 | 4.49e-02 |
| LUSC | HLA-DOA-001 | chr6_33005780_- | 3.74e-01 | 4.02e-01 | -2.17e+00 | 3.01e-02 | 4.91e-02 | -2.85e-02 |
| SKCM | HLA-DOA-001 | chr6_33005645_- | 2.76e-01 | 3.09e-01 | -1.98e+00 | 4.82e-02 | 4.91e-02 | -3.34e-02 |
| COAD | HLA-DOA-001 | chr6_33005380_- | 7.99e-01 | 8.71e-01 | -2.24e+00 | 2.49e-02 | 3.71e-02 | -7.12e-02 |
| COAD | HLA-DOA-001 | chr6_33005409_- | 1.66e-01 | 2.86e-01 | -2.20e+00 | 2.78e-02 | 3.85e-02 | -1.20e-01 |
| COAD | HLA-DOA-001 | chr6_33005742_- | 2.32e-01 | 3.04e-01 | -2.76e+00 | 5.72e-03 | 1.72e-02 | -7.27e-02 |
| BLCA | HLA-DOA-001 | chr6_33005380_- | 8.26e-01 | 7.86e-01 | 2.21e+00 | 2.73e-02 | 4.98e-02 | 4.07e-02 |
| BLCA | HLA-DOA-001 | chr6_33005693_- | 1.68e-01 | 1.32e-01 | 2.13e+00 | 3.31e-02 | 4.98e-02 | 3.56e-02 |
| BLCA | HLA-DOA-001 | chr6_33005706_- | 1.58e-01 | 2.07e-01 | -2.08e+00 | 3.73e-02 | 4.98e-02 | -4.97e-02 |
| STAD | HLA-DOA-001 | chr6_33005645_- | 2.98e-01 | 3.46e-01 | -2.46e+00 | 1.41e-02 | 4.96e-02 | -4.81e-02 |
| STAD | HLA-DOA-001 | chr6_33005784_- | 1.87e-01 | 1.32e-01 | 2.22e+00 | 2.62e-02 | 4.96e-02 | 5.50e-02 |
| LIHC | HLA-DOA-001 | chr6_33005693_- | 1.42e-01 | 2.08e-01 | -2.64e+00 | 8.23e-03 | 4.07e-02 | -6.55e-02 |
| LIHC | HLA-DOA-001 | chr6_33005805_- | 1.52e-01 | 1.75e-01 | -2.15e+00 | 3.12e-02 | 4.60e-02 | -2.31e-02 |
| PCPG | HLA-DOA-001 | chr6_33005300_- | 2.25e-01 | 2.91e-01 | -1.97e+00 | 4.90e-02 | 4.98e-02 | -6.53e-02 |
| PAAD | HLA-DOA-001 | chr6_33005798_- | 2.79e-01 | 2.42e-01 | 2.04e+00 | 4.11e-02 | 4.89e-02 | 3.66e-02 |
| PAAD | HLA-DOA-001 | chr6_33005854_- | 3.39e-01 | 2.93e-01 | 2.42e+00 | 1.56e-02 | 4.66e-02 | 4.62e-02 |
| GBM | HLA-DOA-001 | chr6_33005409_- | 1.93e-01 | 2.30e-01 | -2.26e+00 | 2.41e-02 | 4.96e-02 | -3.70e-02 |
| GBM | HLA-DOA-001 | chr6_33005742_- | 2.61e-01 | 1.81e-01 | 2.51e+00 | 1.22e-02 | 4.96e-02 | 8.02e-02 |
| ESCA | HLA-DOA-001 | chr6_33005675_- | 1.99e-01 | 2.64e-01 | -2.27e+00 | 2.30e-02 | 4.99e-02 | -6.54e-02 |
| THYM | HLA-DOA-001 | chr6_33005675_- | 2.11e-01 | 1.68e-01 | 2.50e+00 | 1.24e-02 | 4.73e-02 | 4.23e-02 |
| UVM | HLA-DOA-001 | chr6_33005854_- | 3.46e-01 | 4.86e-01 | -1.97e+00 | 4.91e-02 | 4.93e-02 | -1.40e-01 |
| KICH | HLA-DOA-001 | chr6_33005250_- | 2.21e-01 | 2.77e-01 | -2.11e+00 | 3.51e-02 | 4.94e-02 | -5.64e-02 |
| KICH | HLA-DOA-001 | chr6_33005798_- | 2.28e-01 | 2.95e-01 | -2.01e+00 | 4.46e-02 | 4.94e-02 | -6.68e-02 |
| CHOL | HLA-DOA-001 | chr6_33005238_- | 2.00e-01 | 1.46e-01 | 2.08e+00 | 3.73e-02 | 4.94e-02 | 5.34e-02 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| KIRC | HLA-DOA-001 | chr6_33005250_- | 2.87e-01 | 2.59e-01 | 2.38e+00 | 1.74e-02 | 2.58e-02 | 2.86e-02 |
| KIRC | HLA-DOA-001 | chr6_33005780_- | 4.12e-01 | 3.68e-01 | 3.04e+00 | 2.35e-03 | 6.66e-03 | 4.33e-02 |
| KIRC | HLA-DOA-001 | chr6_33005797_- | 2.16e-01 | 1.86e-01 | 2.75e+00 | 5.97e-03 | 1.27e-02 | 3.08e-02 |
| KIRC | HLA-DOA-001 | chr6_33005854_- | 3.74e-01 | 3.14e-01 | 4.01e+00 | 6.20e-05 | 4.79e-04 | 5.97e-02 |
| LUAD | HLA-DOA-001 | chr6_33005380_- | 8.42e-01 | 8.04e-01 | 2.86e+00 | 4.25e-03 | 1.04e-02 | 3.81e-02 |
| LUAD | HLA-DOA-001 | chr6_33005392_- | 1.62e-01 | 1.16e-01 | 3.43e+00 | 5.94e-04 | 2.83e-03 | 4.53e-02 |
| HNSC | HLA-DOA-001 | chr6_33005250_- | 2.81e-01 | 2.07e-01 | 2.81e+00 | 4.98e-03 | 8.00e-03 | 7.34e-02 |
| HNSC | HLA-DOA-001 | chr6_33005380_- | 8.24e-01 | 7.38e-01 | 2.96e+00 | 3.12e-03 | 5.51e-03 | 8.58e-02 |
| HNSC | HLA-DOA-001 | chr6_33005798_- | 2.99e-01 | 2.08e-01 | 2.45e+00 | 1.41e-02 | 1.85e-02 | 9.08e-02 |
| HNSC | HLA-DOA-001 | chr6_33005853_- | 1.85e-01 | 1.28e-01 | 2.34e+00 | 1.94e-02 | 2.40e-02 | 5.76e-02 |
| LUSC | HLA-DOA-001 | chr6_33005238_- | 1.87e-01 | 1.27e-01 | 4.12e+00 | 3.86e-05 | 5.59e-04 | 6.01e-02 |
| LUSC | HLA-DOA-001 | chr6_33005429_- | 2.04e-01 | 1.36e-01 | 3.45e+00 | 5.69e-04 | 3.26e-03 | 6.78e-02 |
| LUSC | HLA-DOA-001 | chr6_33005675_- | 1.89e-01 | 1.40e-01 | 3.42e+00 | 6.23e-04 | 3.41e-03 | 4.84e-02 |
| LUSC | HLA-DOA-001 | chr6_33005742_- | 2.70e-01 | 1.96e-01 | 2.78e+00 | 5.48e-03 | 1.34e-02 | 7.38e-02 |
| LUSC | HLA-DOA-001 | chr6_33005807_- | 1.56e-01 | 1.18e-01 | 2.59e+00 | 9.60e-03 | 1.91e-02 | 3.77e-02 |
| COAD | HLA-DOA-001 | chr6_33005645_- | 2.79e-01 | 2.10e-01 | 2.00e+00 | 4.57e-02 | 4.67e-02 | 6.99e-02 |
| KIRP | HLA-DOA-001 | chr6_33005238_- | 1.39e-01 | 1.66e-01 | -2.10e+00 | 3.54e-02 | 4.29e-02 | -2.70e-02 |
| KIRP | HLA-DOA-001 | chr6_33005250_- | 2.11e-01 | 2.75e-01 | -3.50e+00 | 4.73e-04 | 3.80e-03 | -6.34e-02 |
| KIRP | HLA-DOA-001 | chr6_33005645_- | 2.16e-01 | 2.73e-01 | -2.43e+00 | 1.50e-02 | 2.88e-02 | -5.70e-02 |
| KIRP | HLA-DOA-001 | chr6_33005853_- | 1.44e-01 | 1.95e-01 | -3.44e+00 | 5.75e-04 | 4.25e-03 | -5.05e-02 |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| BRCA | HLA-DOA-001 | chr6_33005238_- | 2.24e-01 | 1.70e-01 | 5.60e+00 | 2.20e-08 | 1.11e-07 | 5.45e-02 |
| BRCA | HLA-DOA-001 | chr6_33005250_- | 3.24e-01 | 2.42e-01 | 6.76e+00 | 1.34e-11 | 1.09e-10 | 8.21e-02 |
| BRCA | HLA-DOA-001 | chr6_33005300_- | 2.04e-01 | 1.56e-01 | 4.60e+00 | 4.22e-06 | 1.42e-05 | 4.74e-02 |
| BRCA | HLA-DOA-001 | chr6_33005309_- | 1.90e-01 | 1.46e-01 | 3.03e+00 | 2.43e-03 | 4.23e-03 | 4.39e-02 |
| BRCA | HLA-DOA-001 | chr6_33005380_- | 8.44e-01 | 8.05e-01 | 3.19e+00 | 1.40e-03 | 2.61e-03 | 3.86e-02 |
| BRCA | HLA-DOA-001 | chr6_33005645_- | 3.26e-01 | 2.35e-01 | 5.81e+00 | 6.16e-09 | 3.39e-08 | 9.07e-02 |
| BRCA | HLA-DOA-001 | chr6_33005742_- | 2.88e-01 | 1.93e-01 | 5.33e+00 | 9.92e-08 | 4.46e-07 | 9.51e-02 |
| BRCA | HLA-DOA-001 | chr6_33005780_- | 4.56e-01 | 3.70e-01 | 6.49e+00 | 8.70e-11 | 6.35e-10 | 8.58e-02 |
| BRCA | HLA-DOA-001 | chr6_33005797_- | 2.50e-01 | 1.95e-01 | 4.54e+00 | 5.58e-06 | 1.83e-05 | 5.50e-02 |
| BRCA | HLA-DOA-001 | chr6_33005798_- | 3.24e-01 | 2.43e-01 | 6.07e+00 | 1.29e-09 | 7.81e-09 | 8.18e-02 |
| BRCA | HLA-DOA-001 | chr6_33005853_- | 1.96e-01 | 1.61e-01 | 3.76e+00 | 1.67e-04 | 3.97e-04 | 3.57e-02 |
| BRCA | HLA-DOA-001 | chr6_33005854_- | 4.15e-01 | 2.95e-01 | 8.95e+00 | 3.47e-19 | 7.75e-18 | 1.19e-01 |
| KIRC | HLA-DOA-001 | chr6_33005238_- | 1.92e-01 | 1.75e-01 | 2.03e+00 | 4.27e-02 | 4.63e-02 | 1.71e-02 |
| LUAD | HLA-DOA-001 | chr6_33005742_- | 2.42e-01 | 1.75e-01 | 2.93e+00 | 3.42e-03 | 8.88e-03 | 6.78e-02 |
| THCA | HLA-DOA-001 | chr6_33005300_- | 1.57e-01 | 1.47e-01 | 1.97e+00 | 4.91e-02 | 4.93e-02 | 1.02e-02 |
| THCA | HLA-DOA-001 | chr6_33005380_- | 8.27e-01 | 7.88e-01 | 2.57e+00 | 1.00e-02 | 1.71e-02 | 3.90e-02 |
| LUSC | HLA-DOA-001 | chr6_33005380_- | 8.26e-01 | 7.60e-01 | 2.64e+00 | 8.41e-03 | 2.23e-02 | 6.61e-02 |
| COAD | HLA-DOA-001 | chr6_33005797_- | 2.68e-01 | 2.09e-01 | 2.11e+00 | 3.45e-02 | 4.02e-02 | 5.94e-02 |
| BLCA | HLA-DOA-001 | chr6_33005250_- | 2.92e-01 | 1.99e-01 | 2.08e+00 | 3.72e-02 | 4.50e-02 | 9.30e-02 |
| BLCA | HLA-DOA-001 | chr6_33005854_- | 3.70e-01 | 2.22e-01 | 2.58e+00 | 9.86e-03 | 3.32e-02 | 1.47e-01 |
| STAD | HLA-DOA-001 | chr6_33005780_- | 4.32e-01 | 2.43e-01 | 2.67e+00 | 7.68e-03 | 2.67e-02 | 1.89e-01 |
| LIHC | HLA-DOA-001 | chr6_33005238_- | 2.18e-01 | 3.01e-01 | -1.96e+00 | 4.96e-02 | 4.98e-02 | -8.30e-02 |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for HLA-DOA |
| TFs related to HLA-DOA. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| BRCA | PLAGL2 | HLA-DOA | 3.24e+00 | 9.33e-03 | 4.47e+00 | 9.80e-01 | Female-biased |
| MESO | FOXD2 | HLA-DOA | 4.08e+00 | 9.85e-01 | 2.38e+00 | 1.81e-03 | Male-biased |
| MESO | MYNN | HLA-DOA | 4.06e+00 | 9.84e-01 | 2.45e+00 | 2.43e-03 | Male-biased |
| MESO | NKX3-2 | HLA-DOA | 4.27e+00 | 9.87e-01 | 2.78e+00 | 3.86e-03 | Male-biased |
| MESO | ZNF334 | HLA-DOA | 3.89e+00 | 9.83e-01 | 1.62e+00 | 2.25e-04 | Male-biased |
| MESO | ZNF354B | HLA-DOA | 4.16e+00 | 9.82e-01 | 2.86e+00 | 7.03e-03 | Male-biased |
| HLA-DOA related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for HLA-DOA |
| RBPs related to ES in HLA-DOA. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| HLA-DOA related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs4713630 | chr6:33505164:T:C | - | -0.191055110874447 | 0.00286926159070459 | STAD | Female-baised eQTL |
| rs3857558 | chr6:33509236:G:T | - | -0.191055110874447 | 0.00286926159070459 | STAD | Female-baised eQTL |
| rs4713633 | chr6:33509363:G:A | - | -0.191055110874447 | 0.00286926159070459 | STAD | Female-baised eQTL |
| rs9368765 | chr6:33510227:T:G | - | -0.191055110874447 | 0.00286926159070459 | STAD | Female-baised eQTL |
| rs3843520 | chr6:33511137:G:A | - | -0.191055110874447 | 0.00286926159070459 | STAD | Female-baised eQTL |
| rs3843521 | chr6:33511162:T:C | - | -0.191055110874447 | 0.00286926159070459 | STAD | Female-baised eQTL |
| rs4713629 | chr6:33497139:T:C | - | -0.200073134863025 | 0.00501391114713595 | STAD | Female-baised eQTL |
| rs34897283 | chr6:33494159:G:A | - | -0.178862467957493 | 0.00697263387311168 | STAD | Female-baised eQTL |
| rs6910219 | chr6:33494251:T:A | - | -0.178862467957493 | 0.00697263387311168 | STAD | Female-baised eQTL |
| rs6907702 | chr6:33511997:T:C | - | -0.196277413064325 | 0.00712815807348557 | STAD | Female-baised eQTL |
| rs9261844 | chr6:30414433:G:A | - | 0.135007825631455 | 0.0440928821754033 | STAD | Female-baised eQTL |
| rs62400444 | chr6:24327867:G:A | - | 0.14775556636928 | 0.00549691651335633 | BLCA | Female-baised eQTL |
| rs7765678 | chr6:24330316:T:C | - | 0.14775556636928 | 0.00549691651335633 | BLCA | Female-baised eQTL |
| rs62400448 | chr6:24335719:A:C | - | 0.14775556636928 | 0.00549691651335633 | BLCA | Female-baised eQTL |
| rs11968757 | chr6:35739577:C:T | - | 0.140430440198122 | 0.0259137158022351 | BLCA | Female-baised eQTL |
| rs58467060 | chr6:24327483:T:G | - | 0.10176853654664 | 0.0313063592568549 | BLCA | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs75057504 | chr6:32242166:T:C | - | 0.120314910441579 | 0.0260083550011241 | KIRP | Male-baised eQTL |
| rs111288921 | chr6:35513098:C:A | - | 0.0997091749536349 | 0.0193142828294613 | LIHC | Male-baised eQTL |
| rs4713877 | chr6:35513871:T:C | - | 0.0997091749536349 | 0.0193142828294613 | LIHC | Male-baised eQTL |
| rs6903200 | chr6:35514254:G:A | - | 0.0997091749536349 | 0.0193142828294613 | LIHC | Male-baised eQTL |
| rs12110645 | chr6:35515202:G:A | - | 0.0997091749536349 | 0.0193142828294613 | LIHC | Male-baised eQTL |
| rs4711419 | chr6:35510146:A:G | - | 0.0994268350316111 | 0.0202488186013037 | LIHC | Male-baised eQTL |
| rs9469718 | chr6:34122833:A:G | - | 0.112948399984261 | 0.0374112061380978 | STAD | Male-baised eQTL |
| rs12211656 | chr6:39281409:A:G | - | 0.08179759093998 | 0.000114479828951333 | KIRC | Male-baised eQTL |
| rs6929749 | chr6:25025494:T:C | - | 0.0560858999473813 | 0.0379732546002044 | KIRC | Male-baised eQTL |
| rs12111365 | chr6:42115698:T:G | - | 0.0533800560592591 | 0.017007792173506 | BLCA | Male-baised eQTL |
| rs112610212 | chr6:42115908:T:C | - | 0.0515942631689182 | 0.031052498421807 | BLCA | Male-baised eQTL |
| rs28870778 | chr6:42115284:C:G | - | 0.0502708125054522 | 0.0446292727223372 | BLCA | Male-baised eQTL |
| rs11751840 | chr6:42110863:A:G | - | 0.0505078251914616 | 0.0453753104132907 | BLCA | Male-baised eQTL |
| rs4386816 | chr6:31279358:T:C | - | 0.0309232301546903 | 0.0222811310992499 | COAD | Male-baised eQTL |
| rs62398919 | chr6:33748857:T:G | - | 0.0343305716649759 | 0.0406229557312157 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of HLA-DOA |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000204252 | HLA-DOA | C2931456 | Prostate cancer, familial | 1 | CTD_human |
| ENSG00000204252 | HLA-DOA | C4722327 | PROSTATE CANCER, HEREDITARY, 1 | 1 | CTD_human |
